Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery

1. A method for inhibiting aggregation of interferon alpha-2b in a biphasic vesicle composition which method comprises adding argmine or a pharmaceutically acceptable salt thereof in a sufficient amount to inhibit aggregation of interferon alpha-2b, thereby inhibiting aggregation of interferon alpha-2b in the biphasic vesicle composition.

2. The method of claim 1 , wherein the arginine or a pharmaceutically acceptable salt thereof is arginine hydrochloride.

3. The method of claim 1 , wherein the arginine or a pharmaceutically acceptable salt thereof is L-arginine or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , wherein the arginine or a pharmaceutically acceptable salt thereof is L-arginine hydrochloride.

5. The method of claim 4 , wherein the L-arginine hydrochloride is present in an amount of 0.1 to 5 mg/g.